OBJECTIVES: To assess the frequency of clinical features of Sjogren's syndrome (SS) in patients with multiple sclerosis (MS) receiving treatment with disease-modifying drugs (DMDs) or naïve to treatment and the possible association with clinical, cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) parameters. METHODS: A multicentre cross-sectional observational study was designed, based on a structured neurologist-administered questionnaire to 440 patients. RESULTS: Twenty-eight of 230 (12%) patients receiving treatment with DMDs (DMDs(+)) and 14 of 210 (6.6%) treatment-naïve patients (DMDs(-) ) showed clinical features of SS. Four primary SS were diagnosed, two of which were DMDs(+) and two were DMDs(-) . Sicca symptoms w...
In this thesis I used magnetic resonance imaging (MRI) to study patients with clinically isolated sy...
The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drug...
The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drug...
OBJECTIVES: To assess the frequency of clinical features of Sjogren's syndrome (SS) in patients wi...
Objectives - To assess the frequency of clinical features of Sjogren's syndrome (SS) in patients wit...
Background: Multiple sclerosis (MS) like disease may be a feature of central nervous system (CNS) in...
OBJECTIVE: To determine the prevalence of neurological and magnetic resonance imaging (MRI) abnormal...
Introduction: Neurological involvements were shown in 20% of patients with Primary Sjogren's Syndrom...
Objectives : To investigate the clinical characteristics of Sjögren's syndrome (SS). Methods : We. r...
OBJECTIVES: To investigate the impact of the 2017 revisions of McDonald criteria on the diagnosis o...
OBJECTIVE--To compare the abnormalities shown by magnetic resonance imaging of the brain in three cl...
PURPOSE: To describe drug-use patterns in patients with multiple sclerosis (MS) using disease-modify...
Objectives: To assess subclinical central nervous system (CNS) involvement in primary Sjögren syndr...
Background: Rheumatologic diseases may cause neurologic disorders that mimic multiple sclerosis (MS)...
OBJECTIVE: To improve the characterization of asymptomatic subjects with brain magnetic resonance i...
In this thesis I used magnetic resonance imaging (MRI) to study patients with clinically isolated sy...
The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drug...
The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drug...
OBJECTIVES: To assess the frequency of clinical features of Sjogren's syndrome (SS) in patients wi...
Objectives - To assess the frequency of clinical features of Sjogren's syndrome (SS) in patients wit...
Background: Multiple sclerosis (MS) like disease may be a feature of central nervous system (CNS) in...
OBJECTIVE: To determine the prevalence of neurological and magnetic resonance imaging (MRI) abnormal...
Introduction: Neurological involvements were shown in 20% of patients with Primary Sjogren's Syndrom...
Objectives : To investigate the clinical characteristics of Sjögren's syndrome (SS). Methods : We. r...
OBJECTIVES: To investigate the impact of the 2017 revisions of McDonald criteria on the diagnosis o...
OBJECTIVE--To compare the abnormalities shown by magnetic resonance imaging of the brain in three cl...
PURPOSE: To describe drug-use patterns in patients with multiple sclerosis (MS) using disease-modify...
Objectives: To assess subclinical central nervous system (CNS) involvement in primary Sjögren syndr...
Background: Rheumatologic diseases may cause neurologic disorders that mimic multiple sclerosis (MS)...
OBJECTIVE: To improve the characterization of asymptomatic subjects with brain magnetic resonance i...
In this thesis I used magnetic resonance imaging (MRI) to study patients with clinically isolated sy...
The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drug...
The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drug...